In recent years, targeted therapies, particularly poly(ADP-ribose) polymerase (PARP) inhibitors, have emerged as effective treatments for high-grade serous carcinoma (HGSC) of the ovary, especially in tumors with defective homologous recombination repair or BRCA1/2 mutations.21 The gene discussed is BRCA1; the disease is serous adenocarcinoma.